Subscribe to RSS

DOI: 10.1055/s-0045-1815711
Availability, Prices, and Affordability of Essential Cardiovascular Medicines in Tripoli, Libya: A Cross-Sectional Survey
Authors

Abstract
Background
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. In many low-income and middle-income countries, these fatalities are exacerbated by poor accessibility and affordability of essential cardiovascular medications.
Aim
This study was aimed to investigate the availability, prices, and affordability of essential CVD medications, and to determine the key factors influencing these outcomes in Tripoli, Libya.
Methods
The World Health Organization/Health Action International method was employed to survey a convenience sample of 200 community pharmacies for 17 essential CVD medications in September 2023. Data on availability, presence of an import sticker, and prices of the originator brand (OB) and lowest-priced generic (LPG) for each medication were collected. The main measured variables were the percentage availability, the proportion of medications with an import sticker, the median price ratio (MPR), the price variation among pharmacies, the ratio of OB to LPG prices, and the affordability. The affordability was expressed in terms of the number of days a lowest-paid government employee would need to work to pay for a 1-month supply of medication. Descriptive statistics using Excel and R summarized availability, prices, and affordability. The Mann–Whitney U test compared metrics between originator and generic medicines. Spearman's rank correlation (ρ) assessed variable relationships, and a mixed-effects linear regression model identified price determinants.
Results
The mean availability of OBs was significantly lower than that of LPGs (25.6 vs. 55.9%, p < 0.007). A total of 13% of OBs had an import sticker, whereas only 1% of LPGs did. Dispensing prices were higher than international reference prices for both OBs (MPR = 7.4) and LPGs (MPR = 3.7). Price variation across pharmacies exceeded a 4-fold difference for both OBs and LPGs. The OB/LPG price ratio was greater than 2. The cost of 1-month treatment courses exceeded 1-day wage on average for both OBs (2.9, 95% confidence interval [CI]: 1.7–4.1) and LPGs (1.5, 95% CI: 0.7–2.3). The availability level was negatively correlated with the days' wages (ρ = − 0.42, p < 0.04) and positively correlated with the number of manufacturing countries and competing manufacturers (ρ = 0.5, p < 0.01). Conversely, the required number of days' wages was positively correlated with the median unit price (ρ = 0.59, p < 0.01). Prices were significantly influenced by drug type (OB/LPG), drug class, and the region of manufacturer (Africa/ Asia).
Conclusion
Essential CVD medications in Tripoli were found to have suboptimal availability and poor affordability. The price variation and the lack of importer information suggest systemic issues in the supply chain and distribution that require policy interventions.
Keywords
availability - affordability - price - essential medicines - cardiovascular diseases - LibyaPublication History
Received: 17 September 2025
Accepted: 09 December 2025
Article published online:
19 February 2026
© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Netala VR, Teertam SK, Li H, Zhang Z. A comprehensive review of cardiovascular disease management: cardiac biomarkers, imaging modalities, pharmacotherapy, surgical interventions, and herbal remedies. Cells 2024; 13 (17) 1471-1540
- 2 World Health Organization. Cardiovascular diseases (CVDs). Accessed September 17, 2025 at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- 3 Harrison MA, Marfo AFA, Annan A, Ankrah DNA. Access to cardiovascular medicines in low- and middle-income countries: a mini review. Glob Health Res Policy 2023; 8 (01) 17-33
- 4 World Heart Federation. Libya-World Heart Observatory. Accessed September 11, 2025 at: https://world-heart-federation.org/world-heart-observatory/countries/libya/
- 5 Hakim S, Chowdhury MAB, Haque MA, Ahmed NU, Paul GK, Uddin MJ. The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: the case of Bangladesh. PLOS Glob Public Health 2022; 2 (11) e0001154
- 6 Zhu JZ, Manne-Goehler J, Agarwal A. et al; Global Health & Population Project on Access to Care for Cardiometabolic Disease (HPACC). Medication use for cardiovascular disease prevention in 40 low-and middle-income countries. J Am Coll Cardiol 2023; 81 (06) 620-622
- 7 Chow CK, Nguyen TN, Marschner S. et al; PURE Study. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health 2020; 5 (11) e002640
- 8 Husain MJ, Datta BK, Kostova D. et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc 2020; 9 (09) e015302
- 9 Libyan Ministry of Health. Libyan Essential Medicines List. 2019 :1–77. Accessed 17 September 17, 2025 at: https://reliefweb.int/report/libya/libyan-essential-medicines-list-1st-edition
- 10 WHO Country Office. WHO Country Office, Libya: annual report 2022. 2023: 1-48 . Accessed September 17, 2025 at: https://iris.who.int/handle/10665/368511
- 11 Msalam O. Country report state of Libya. The European Association of Preventive Cardiology. 2018 . Accessed September 17, 2025 at: https://www.escardio.org/static-file/Escardio/Subspecialty/EAPC/Country%20of%20the%20month/Documents/libya-country-of-the-month-full-report.pdf
- 12 World Health Organization and Health Action International. Measuring Medicine Prices, Availability, Affordability and Price Components. 2nd ed. 2008
- 13 Management Sciences for Health (MSH). MSH International Medical Products Price Guide 2015 ed. MSH; 2016: 443
- 14 Abdel Rida N, Mohamed Ibrahim MI, Babar ZUD. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon. BMC Health Serv Res 2019; 19 (01) 973-986
- 15 Kaiser AH, Hehman L, Forsberg BC, Simangolwa WM, Sundewall J. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. PLoS One 2019; 14 (12) e0226169
- 16 Wang Q, Wang H, Mu Y, Cheng Y, Gao Z, Yang Y. A study on the availability, price and affordability of drugs for preventing and treating cardiovascular diseases based on information from online pharmacies in China. Drugs Ther Perspect 2017; 33: 41-46
- 17 Saeed A, Saeed F, Saeed H. et al. Access to essential cardiovascular medicines in Pakistan: a national survey on the availability, price, and affordability, using WHO/HAI methodology. Front Pharmacol 2021; 11: 595008-595020
- 18 Dzudie A, Njume E, Abanda M. et al. Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study. PLoS One 2020; 15 (03) e0229307
- 19 Ashames A, Abushoffa A, Tabet M, Saidan RB, Lagha B. Impact of the Libyan Conflict on quality of medicines available in the local market. J Chem Pharm Res 2019; 11 (01) 20-27
- 20 Araja D, Sumilo E. Pharmaceutical enterprises' market entry strategies. Presented at: New Challenges in Economic and Business Development – 2020: Economic Inequality and Well-Being; 2020 https://dspace.lu.lv/dspace/handle/7/54167
- 21 Ferrario A, Humbert T, Kanavos P, Pedersen HB. Strategic procurement and international collaboration to improve access to medicines. Bull World Health Organ 2017; 95 (10) 720-722
- 22 Sanket JS, Ankitkumar NP. Review on pharmaceutical supply chain resilience: strategies for managing disruptions and ensuring continuity. World J Curr Med Pharm Res 2024; 6 (03) 8-14
- 23 Suprapti B, Yusuf M, Debby Saraswati M, Febriana Astuti S, Damayanti D. The ABC analysis of drug use and cost in cardiology outpatients-National Health Insurance. J Farm Ilmu Kefarmasian Indones 2022; 9 (01) 193-199
- 24 Olajide JO, Otokiti BO, Nwani S, Ogunmokun AS, Adekunle BI, Efekpogua J. Designing a financial planning framework for managing SLOB and write-off risk in fast-moving consumer goods (FMCG). IRE J. 2020 ;4(4):259–266. https://www.irejournals.com/paper-details/1709016
